

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 September 2005 (01.09.2005)

PCT

(10) International Publication Number
WO 2005/079827 A2

(51) International Patent Classification⁷: **A61K 38/00**

(21) International Application Number:
PCT/JP2005/003689

(22) International Filing Date: 25 February 2005 (25.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2004-050520 25 February 2004 (25.02.2004) JP
60/566,077 29 April 2004 (29.04.2004) US

(71) Applicant (for all designated States except US): **FUJISAWA PHARMACEUTICAL CO., LTD.** [JP/JP];
4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka
5418514 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **NAOE, Yoshinori**
[JP/JP]; 4034-18-103, Izumi-cho, Izumi-ku, Yoko-
hama-shi, Kanagawa 2450016 (JP). **INOUE, Takeshi**
[JP/JP]; c/o FUJISAWA PHARMACEUTICAL CO., Ltd.,
4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka
5418514 (JP). **KANO, Yasuhiko** [JP/JP]; c/o Tochigi
Cancer Center, 4-9-13, Yunnan, Utsunomiya-shi, Tochigi
3200834 (JP).

(74) Agent: **TAKASHIMA, Hajime**; Meiji Yasuda Seimei Os-
aka Midosuji Bldg., 1-1, Fushimimachi 4-chome, Chuo-ku,
Osaka-shi, Osaka 5410044 (JP).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: ANTITUMOR AGENT

(57) Abstract: An antitumor agent containing, in combination, at least one kind of antitumor agent selected from the group consist-
ing of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a
taxane antitumor agent, and a histone deacetylase inhibitor. According to the present invention, an antitumor agent causing reduced
side effects and having a superior antitumor activity can be provided.



WO 2005/079827 A2

DESCRIPTION**ANTITUMOR AGENT****TECHNICAL FIELD**

The present invention relates to pharmaceutical
5 compositions comprising, in combination, an antitumor agent
selected from an antitumor agent that forms a cross-link with
DNA and shows an antitumor effect, an antimetabolite antitumor
agent and a taxane antitumor agent, and a pharmaceutical agent
that remarkably enhances the antitumor effect and methods of
10 using such agents.


BACKGROUND ART

In the chemotherapy of tumors, particularly malignant
tumors, in general, it is rare to achieve a desired antitumor
effect by administration of a single antitumor agent, and in
15 clinical situations, therefore, multiple drug therapy using
two or more agents having different action mechanisms has been
employed with the aim of increasing its effect. This
combination therapy aims at alleviating side effects and
enhancing antitumor action by combining antitumor agents
20 having different action mechanisms, thereby to 1) decrease
insensitive cell population, 2) prevent or delay development
of drug resistance, 3) disperse toxicity by a combination of
pharmaceutical agents with different toxicities and the like.
However, random combinations of pharmaceutical agents with
25 different action mechanisms for a combination therapy do not
necessarily provide an antitumor effect-enhancing action or
synergy.


It has been reported that histone deacetylase (HDAC)
inhibitors induce high acetylation of histone and, as a result,
30 induces transcription regulating activity on various genes,
cell cycle inhibitory activity and apoptosis. Histone
deacetylase inhibitors are also known as a potent anticancer
agent (see JP-B-7-64872, Experimental Cell Research, US (1998),

vol. 241, pp. 126-133).

For example, a compound represented by the formula (I)



or a pharmaceutically acceptable salt thereof (hereinafter to
 5 be also referred to as compound A), particularly a
 stereoisomer represented by the formula (II)



(hereinafter to be also referred to as FK228) or a
 pharmaceutically acceptable salt thereof are histone
 10 deacetylase inhibitors and reported to show a potent antitumor
 activity (see JP-B-7-64872 (corresponding to US Patent No.
 4977138), Experimental Cell Research, US (1998), vol. 241, pp.
 126-133).

However, a combined use of a histone deacetylase
 15 inhibitor and an antitumor agent that forms a cross-link with


DNA and shows an antitumor effect, such as cisplatin and the like, an antimetabolite antitumor agent such as 5-fluorouracil and the like or a taxane antitumor agent, all of which are conventionally widely used as antitumor agents, as well as an
5 effect afforded by the combined use have not been reported yet.

DISCLOSURE OF THE INVENTION

It is therefore an object of the present invention to provide an antitumor agent comprising, in combination, an antitumor agent selected from an antitumor agent that forms a
10 cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, and a pharmaceutical agent that remarkably enhances the antitumor effect, which reduces side effects and exhibits a superior antitumor activity.

15 As a result of intensive studies, the present inventors have found that a histone deacetylase inhibitor, particularly compound A known to have a potent histone deacetylase inhibitory activity, also remarkably enhances the antitumor effect of known antitumor agents: an antitumor agent that
20 forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, which resulted in the completion of the present invention. Accordingly, the present invention provides the following.

[1] An antitumor agent and pharmaceutical compositions
25 comprising, in combination, at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, and a histone deacetylase inhibitor and methods of treating
30 patients comprising administering such compositions and agents.
[2] The antitumor agent according to the above-mentioned [1], wherein the histone deacetylase inhibitor is a compound represented by the formula (I)



its reduction product, analogs, prodrugs or a pharmaceutically acceptable salt thereof.

[3] The antitumor agent according to the above-mentioned [2],
 5 wherein the antitumor agent that forms a cross-link with DNA and shows an antitumor effect is a platinum compound antitumor agent or an alkylating antitumor agent.

[4] The antitumor agent according to the above-mentioned [3], wherein the platinum compound antitumor agent is cisplatin.

10 [5] The antitumor agent according to the above-mentioned [2], wherein the antimetabolite antitumor agent is 5-fluorouracil.


[6] The antitumor agent according to the above-mentioned [2], wherein the taxane antitumor agent is at least one of paclitaxel and docetaxel.

15 [7] The antitumor agent according to any of the above-mentioned [1] to [6], which is an antitumor agent for lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian cancer, musculoskeletal sarcoma, bladder cancer, leukemia, kidney cancer or prostate cancer.

20 [8] An antitumor effect enhancer for at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an

antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, which comprises a histone deacetylase inhibitor as an active ingredient, and methods of treating patients comprising administering such compositions and agents.

- 5 [9] The enhancer according to the above-mentioned [8], wherein the histone deacetylase inhibitor is a compound represented by the formula (I)



- its reduction product, analogs, prodrugs or a pharmaceutically acceptable salt thereof.

- [10] The enhancer according to the above-mentioned [9], wherein the antitumor agent that forms a cross-link with DNA and shows an antitumor effect is a platinum compound antitumor agent or an alkylating antitumor agent.

- 15 [11] The enhancer according to the above-mentioned [10], wherein the platinum compound antitumor agent is cisplatin.


- [12] The enhancer according to the above-mentioned [9], wherein the antimetabolite antitumor agent is 5-fluorouracil.

- [13] The enhancer according to the above-mentioned [9],
20 wherein the taxane antitumor agent is at least one of paclitaxel and docetaxel.

- [14] The enhancer according to any of the above-mentioned [8]

to [13], which is an antitumor effect enhancer for lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian cancer, musculoskeletal sarcoma, bladder cancer, leukemia, kidney cancer or prostate cancer.

- 5 [15] A commercial package comprising a concomitant agent comprising at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, and a written
 10 matter associated therewith, the written matter stating that the concomitant agent can or should be used as an antitumor agent with a histone deacetylase inhibitors.
- [16] The commercial package according to the above-mentioned [15], wherein the histone deacetylase inhibitor is a compound
 15 represented by the formula (I)



its reduction product, analogs, prodrugs or a pharmaceutically acceptable salt thereof.

- [17] The commercial package according to the above-mentioned
 20 [16], wherein the antitumor agent that forms a cross-link with DNA and shows an antitumor effect is a platinum compound antitumor agent or an alkylating antitumor agent.


[18] The commercial package according to the above-mentioned [17], wherein the platinum compound antitumor agent is cisplatin.

[19] The commercial package according to the above-mentioned
5 [16], wherein the antimetabolite antitumor agent is 5-fluorouracil.

[20] The commercial package according to the above-mentioned [16], wherein the taxane antitumor agent is at least one of paclitaxel and docetaxel.

10 [21] A commercial package comprising a preparation containing a histone deacetylase inhibitor and a written matter associated therewith, the written matter stating that the preparation can or should be used for enhancing an antitumor effect of at least one kind of antitumor agent selected from
15 the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent.

[22] The commercial package according to the above-mentioned [21], wherein the histone deacetylase inhibitor is a compound
20 represented by the formula (I)



its reduction product, analogs, prodrugs or a pharmaceutically

acceptable salt thereof.

[23] The commercial package according to the above-mentioned [22], wherein the antitumor agent that forms a cross-link with DNA and shows an antitumor effect is a platinum compound antitumor agent or an alkylating antitumor agent.

[24] The commercial package according to the above-mentioned [23], wherein the platinum compound antitumor agent is cisplatin.

[25] The commercial package according to the above-mentioned [22], wherein the antimetabolite antitumor agent is 5-fluorouracil.

[26] The commercial package according to the above-mentioned [22], wherein the taxane antitumor agent is at least one of paclitaxel and docetaxel.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph showing the concept of the analysis.

Fig. 2 is a graph showing the analysis of isobologram of combined use (simultaneous addition) of FK228 and cisplatin on DU-145 cells (Example 1).

Fig. 3 is a graph showing the analysis of isobologram of combined use of FK228 and cisplatin (continuous addition in the order of FK228 $\Rightarrow$ cisplatin) on DU-145 cells (Example 2).

Fig. 4 is a graph showing the analysis of isobologram of combined use of FK228 and cisplatin (continuous addition in the order of cisplatin $\Rightarrow$ FK228) on DU-145 cells (Example 2).

Fig. 5 is a graph showing the analysis of isobologram of combined use (simultaneous addition) of FK228 and 5-fluorouracil on DU-145 cells (Example 3).

Fig. 6 is a graph showing the analysis of isobologram of combined use of FK228 and 5-fluorouracil (continuous addition in the order of FK228 $\Rightarrow$ 5-fluorouracil) on DU-145 cells (Example 4).

Fig. 7 is a graph showing the analysis of isobologram of

combined use of FK228 and 5-fluorouracil (continuous addition in the order of 5-fluorouracil⇒FK228) on DU-145 cells (Example 4).

Fig. 8 is a graph showing the analysis of isobologram of combined use of FK228 and paclitaxel (continuous addition in the order of paclitaxel⇒FK228) on DU-145 cells (Example 5).

DETAILED DESCRIPTION OF THE INVENTION

Histone deacetylase inhibitors (particularly compound A and FK228) remarkably enhance the antitumor effect of an antitumor agent (particularly platinum compound antitumor agent or alkylating antitumor agent) that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent or a taxane antitumor agent.

Therefore, the antitumor agent of the present invention comprising, in combination, at least one kind of antitumor agent selected from an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, and a histone deacetylase inhibitor affords a higher therapeutic effect against cancer at a smaller dose as compared to the administration of a single antitumor agent selected from an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, or a histone deacetylase inhibitor, and can suppress side effects to a lower level.

BEST MODE FOR CARRING OUT THE INVENTION

The histone deacetylase inhibitor to be used in the present invention is a compound that binds to an active site of histone deacetylase competitively with substrates and/or shows an effect of decreasing the enzyme activity of histone deacetylase or otherwise inhibits enzyme activity and includes compounds known as histone deacetylase inhibitors. To be specific, the aforementioned compound A, a salt thereof and a

derivative thereof (e.g., acetylated compound A, thiol form with reduced S-S bond etc. described in WO 02/06307) can be mentioned. Analogs of FK228 are described in US Patent No. 6403555. In addition, Trichostatin A, sodium butyrate,

5 suberoylanilide hydroxamic acid (SAHA), MS-275, cyclic hydroxamic-acid-containing peptide, Apicidin, Trapoxin and the like are the compounds reported to have a histone deacetylase inhibitory activity. The histone deacetylase inhibitor may be one compound or a mixture of two or more compounds.

10 As the histone deacetylase inhibitor, compound A is preferably used. While compound A may have a stereoisomer (e.g., FK228) based on an asymmetric carbon atom or a double bond, such as an optically active form, a geometric isomer and the like, all these isomers and mixtures thereof are also
15 encompassed in the scope of compound A.

Moreover, solvates (e.g., inclusion compounds (e.g., hydrates etc.)), anhydrous forms and other polymorphic forms or pharmaceutically acceptable salts of the compounds described herein are also encompassed in the scope of the
20 present invention.

In the following description of the specification, unless particularly specified, a mere reference to compound A means a compound group including FK228 and a pharmaceutically acceptable salt, irrespective of the stereoisomerism.

25 The histone deacetylase inhibitors recited above include known and available substances. For example, FK228, which is one of the stereoisomers of compound A, can be obtained by culturing a strain belonging to the genus *Chromobacterium*, which is capable of producing FK228, under aerobic conditions,
30 and harvesting the substance from its culture broth. As the strain belonging to the genus *Chromobacterium*, which is capable of producing FK228, for example, *Chromobacterium violaceum* WB968 (FERM BP-1968) can be mentioned. More

specifically, FK228 can be obtained from a FK228-producing strain as described in JP-B-7-64872 (corresponding to US Patent No. 4977138). FK228 is preferably harvested from a strain belonging to the genus *Chromobacterium*, which is
5 capable of producing FK228, because it can be obtained more easily. Synthetic or semi-synthetic FK228 is also advantageous in that further purification step is not necessary or the number of steps can be reduced. Similarly, compounds A other than FK228 can be also obtained by semi-synthesis or total
10 synthesis by conventionally known methods. To be more specific, it can be produced according to the method reported by Khan W. Li, et al. (J. Am. Chem. Soc., Vol. 118, 7237-7238(1996)).

Other histone deacetylase inhibitors, such as Tricostatin A, sodium butyrate, SAHA, MS-275, cyclic hydroxamic-acid-
15 containing peptide, Apicidin, Trapoxin and the like are commercially available or can be prepared by known methods.

A pharmaceutically acceptable salt of compound A includes salts with a base or an acid addition salt such as salts with inorganic base (e.g., alkali metal salts such as sodium salt,
20 potassium salt etc., alkaline earth metal salts such as calcium salt, magnesium salt etc., ammonium salt), salts with an organic base (e.g., organic amine salts such as triethylamine salt, diisopropylethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt,
25 dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt etc.), inorganic acid addition salts (e.g., hydrochloride, hydrobromide, sulfate, phosphate etc.), organic carboxylic acid or sulfonic acid addition salts (e.g., formate, acetate, trifluoroacetate, maleate, tartrate, fumarate,
30 methanesulfonate, benzenesulfonate, toluenesulfonate etc.), salts with a basic or acidic amino acid (e.g., arginine, aspartic acid, glutamic acid etc.) and the like.

The antitumor agent that forms a cross-link with DNA and

shows an antitumor effect to be used in the present invention may be any antitumor agent as long as it directly acts on DNA and forms a cross-link therewith to show an antitumor effect. Examples thereof include known platinum compound antitumor
5 agents, known alkylating antitumor agent and the like. Specific examples thereof include cisplatin, carboplatin and the like for platinum compound antitumor agent, and cyclophosphamide, merphalan and the like for alkylating antitumor agent. The antitumor agent that forms a cross-link
10 with DNA and shows an antitumor effect may be one kind of compound or two or more kinds of compounds in a mixture.

The antimetabolite antitumor agent to be used in the present invention may be any antimetabolite known as an antitumor agent. Specific examples include 5-fluorouracil,
15 tegafur and the like. The antimetabolite antitumor agent may be one kind of compound or two or more kinds of compounds in a mixture.

The taxane antitumor agent used in the present invention includes various components or semisynthetic products thereof
20 having, in the structure, a taxane skeleton isolated from *Taxusbrevifolia* or pure synthetic products having a taxane skeleton. Specifically, paclitaxel, docetaxel and the like can be mentioned. The taxane antitumor agent may be one kind of compound or two or more kinds of compounds in a mixture.

25 In the present invention, the histone deacetylase inhibitor (particularly compound A) remarkably enhances at least one kind of antitumor agent selected from an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane
30 antitumor agent. Therefore, the antitumor agent and the antitumor effect enhancer of the present invention are useful as therapeutic agents for cancerous diseases including blood cancer, solid tumor etc.; more specifically, lung cancer,

malignant lymphoma (e.g., reticulosarcoma, lymphosarcoma, Hodgkin's disease etc.), cancer of digestive organ (e.g., gastric cancer, gallbladder cancer, bile duct cancer, pancreatic cancer, liver cancer, colon cancer, rectal cancer
5 etc.), breast cancer, ovarian cancer, musculoskeletal sarcoma (e.g., osteosarcoma etc.), bladder cancer, leukemia (e.g., acute leukemia including blast crisis of chronic myeloid leukemia etc.), kidney cancer, prostate cancer and the like.

The at least one kind of antitumor agent selected from
10 the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent may be one kind of compound or two or more compounds administered separately or in a mixture.

15 In the present specification, unless particularly specified, by the "antitumor agent A" is meant "at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a
20 taxane antitumor agent".

The antitumor agent or pharmaceutical compositions of the present invention comprises a histone deacetylase inhibitor and an antitumor agent A in combination (i.e., concomitant agent) and may be any as long as it can comprise a histone
25 deacetylase inhibitor and an antitumor agent A when in use for administration. The antitumor agent of the present invention may be a single preparation obtained by simultaneously preparing a histone deacetylase inhibitor and an antitumor agent A, or a combination of at least two preparations
30 obtained by separately preparing a histone deacetylase inhibitor and an antitumor agent A.

The mode of administration is not particularly limited, and, for example, (1) administration of a composition

containing a histone deacetylase inhibitor and an antitumor agent A, namely, administration of a single preparation, (2) simultaneous administration of two preparations by the same administration route, which are obtained by separately
5 preparing a histone deacetylase inhibitor and an antitumor agent A, (3) staggered administration of two preparations by the same administration route, which are obtained by separately preparing a histone deacetylase inhibitor and an antitumor agent A (e.g., administration in the order of a
10 histone deacetylase inhibitor and an antitumor agent A, or administration thereof in reverse order), (4) simultaneous administration of two preparations by different administration routes, which are obtained by separately preparing a histone deacetylase inhibitor and an antitumor agent A, (5) staggered
15 administration of two preparations by different administration routes, which are obtained by separately preparing a histone deacetylase inhibitor and an antitumor agent A (e.g., administration in the order of a histone deacetylase inhibitor and an antitumor agent A, or administration thereof in reverse
20 order) and the like can be mentioned.

The enhancer of the present invention contains a histone deacetylase inhibitor, and may be any as long as it can comprise a histone deacetylase inhibitor and an antitumor agent A in combination when in use for administration.
25 Accordingly, as long as a histone deacetylase inhibitor is contained, the enhancer of the present invention may contain an antitumor agent A in a single preparation, and even if it does not contain an antitumor agent A, an antitumor agent A can be administered separately as a concomitant agent.

30 The administration mode is not particularly limited and, for example, (1) administration of the enhancer of the present invention containing a histone deacetylase inhibitor and an antitumor agent A in a single preparation, (2) simultaneous

administration of the enhancer of the present invention and an antitumor agent A by the same administration route, (3) staggered administration of the enhancer of the present invention and an antitumor agent A by the same administration route (e.g., administration in the order of an antitumor agent A and the enhancer of the present invention, or administration thereof in reverse order), (4) simultaneous administration of the enhancer of the present invention and an antitumor agent A by different administration routes, (5) staggered administration of the enhancer of the present invention and an antitumor agent A by different administration routes (e.g., administration in the order of an antitumor agent A and the enhancer of the present invention, or administration thereof in reverse order) and the like can be mentioned.

In the present invention, the mixing ratio of the histone deacetylase inhibitor and the antitumor agent A can be, whether they are formulated into a single preparation or separate preparations, in the range of generally 1:100 - 100:1, preferably 1:10 - 10:1, by weight ratio.

When an antitumor agent A is to be formulated into a mixture of two or more kinds thereof, the mixing ratio is not particularly limited. When a mixture of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect and an antimetabolite antitumor agent is to be made, the mixing ratio (weight ratio) is preferably in the range of 1:100 - 100:1; when a mixture of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect and a taxane antitumor agent is to be made, the mixing ratio (weight ratio) is preferably in the range of 1:100 - 100:1; and when a mixture of an antimetabolite antitumor agent and a taxane antitumor agent is to be made, the mixing ratio (weight ratio) is preferably in the range of 1:100-100:1.

It is also preferable to administer the agent

concomitantly with ATRA (all-trans-retinoic acid) (e.g., administration as a combined agent, simultaneous or separate administration as individual preparations), with the aim of enhancing the antitumor effect of the present invention.

5 The pharmaceutical compositions, antitumor agent A and/or histone deacetylase inhibitors of the present invention can be used in the form of a pharmaceutical preparation such as a solid, semisolid or liquid (tablet, pellet, troche, capsule, suppository, cream, ointment, aerosol, powder, liquid,
10 emulsion, suspension, syrup, injection etc.) containing a histone deacetylase inhibitor and/or an antitumor agent A as active ingredient(s), which is suitable for transrectal, intranasal, pulmonary, vaginal, external (topical), oral or parenteral (including subcutaneous, implantation, intravenous
15 and intramuscular) administration.

 The antitumor effect enhancer of the present invention can be used in the form of a pharmaceutical preparation such as a solid, semisolid or liquid (tablet, pellet, troche, capsule, suppository, cream, ointment, aerosol, powder, liquid,
20 emulsion, suspension, syrup, injection etc.) containing a histone deacetylase inhibitor as an active ingredient, which is suitable for transrectal, intranasal, pulmonary, vaginal, external (topical), oral or parenteral (including subcutaneous, implantation, intravenous and intramuscular) administration.

25 The antitumor agent and the antitumor effect enhancer of the present invention can be also produced by conventional methods using various organic or inorganic carriers conventionally used for forming pharmaceutical preparations, such as excipients (e.g., sucrose, starch, mannitol, sorbitol,
30 lactose, glucose, cellulose, talc, calcium phosphate, calcium carbonate etc.), condensation agents (e.g., cellulose, methyl cellulose, hydroxypropyl cellulose, polypropylpyrrolidone, gelatin, gum arabic, polyethylene glycol, sucrose, starch

etc.), disintegrants (e.g., starch, carboxymethyl cellulose, carboxymethyl cellulose calcium salt, hydroxypropylstarch, sodium carboxy methyl starch, sodium hydrogen carbonate, calcium phosphate, calcium citrate etc.), lubricants (e.g.,
5 magnesium stearate, earosil, talc, sodium lauryl sulfate etc.),
corrigents (e.g., citric acid, menthol, glycine, orange powder etc.), preservatives (e.g., sodium benzoate, sodium hydrogen sulfite, methylparaben, propylparaben etc.), stabilizers (citric acid, sodium citrate, acetic acid etc.), suspension
10 agents (e.g., methyl cellulose, polyvinyl pyrrolidone, aluminum stearate etc.), dispersants (e.g., hydroxypropylmethyl cellulose etc.), diluents (e.g., water etc.), wax base materials (e.g., cacao butter, polyethylene glycol, white petrolatum etc.) and the like.

15 The antitumor agent and the antitumor effect enhancer of the present invention can be administered to mammals inclusive of human in the form of the above-mentioned conventional pharmaceutical preparations without any particular limitation. In particular, intravenous, intramuscular or oral
20 administration is preferable.

The dose in the present invention can be set to a lower level than that for separate administration of each of the histone deacetylase inhibitor and the antitumor agent A.

For example, the dose is appropriately determined
25 according to various factors such as body weight and/or age of patients and/or severity of disease and administration route.

For example, when compound A is used as a histone deacetylase inhibitor and cisplatin is used as an antitumor agent A, the daily dose of compound A and cisplatin in
30 combination in the case of an intravenous administration is generally 1-1000 mg, preferably 5-100 mg, more preferably 10-60 mg, per 1 m² of human body surface area, which is given for the treatment by continuous infusion. In this case, the daily

dose of compound A is 0.1-100 mg, preferably 1-50 mg, more preferably 5-30 mg, in the amount of compound A, per 1 m² of human body surface area, and cisplatin is administered in the dose of [the aforementioned dose of a combination of compound
5 A and cisplatin - the dose of compound A].

The present invention encompasses a commercial package comprising a concomitant agent comprising at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an
10 antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent and histone deacetylase inhibitor, and a written matter associated therewith, the written matter stating that the concomitant agent can or should be used as an antitumor agent; and a commercial package comprising a
15 preparation containing a histone deacetylase inhibitor and a written matter associated therewith, the written matter stating that the preparation can or should be used for enhancing an antitumor effect of at least one kind of antitumor agent selected from the group consisting of an
20 antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent.

EXAMPLES

Pharmacological test results showing the usefulness of
25 the present invention are shown in the following.

Using FK228 as a histone deacetylase inhibitor, cisplatin (CDDP) as an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, 5-fluorouracil (5-FU) as an antimetabolite antitumor agent and paclitaxel as a taxane
30 antitumor agent, the effect of the combined use of the histone deacetylase inhibitor and each of the tumor agents was evaluated. For the evaluation test, human prostate cancer cell DU-145 (obtained from ATCC (AMERICAN TYPE CULTURE COLLECTION))

was cultured in 10% fetal bovine serum-containing Dulbecco's Modified Eagle Medium and applied to the test.

Experimental Example 1: effect of combined use (simultaneous addition) of FK228 and cisplatin

5 Prostate cancer cells (6×10^3 cells/well) were cultured in a 96 well plate for 24 hr and FK228 (0.1 nM, 0.2 nM, 0.5 nM, 1 nM, 2 nM, 5 nM, 10 nM, 20 nM and 50 nM), cisplatin (50 nM, 100 nM, 200 nM, 500 nM, 1000 nM, 2000 nM and 5000 nM) or both pharmaceutical agents (simultaneous addition of the
10 combination at the aforementioned concentrations) was/were added to achieve various concentrations. After culture for 24 hr, the cells were washed twice with 1% FBS (Fetal Bovine Serum)-containing PBS(-) (phosphate-buffered saline (calcium magnesium free)). The medium was changed to a drug-free medium
15 and the cells were further cultured for 96 hr. FK228 was dissolved in ethanol and diluted with a medium before use, and cisplatin was diluted with a medium before use.

The antitumor activity after each treatment was evaluated by MTT assay. To be specific, 3-(4,5-dimethylthiazol-2-yl)-
20 2,5-diphenyltetrazonium bromide (MTT) was dissolved in PBS at a concentration of 2.5 mg/mL, 20 μ l thereof was added to each well and cultured for 4 hr. Formazan formed by living cells was dissolved by adding acidic isopropanol (100 μ l) and the absorbance of each well was measured at a wavelength of 580 nm.

25 With the absorbance (OD) of non-treated cells as 100%, concentration-response curves of antitumor activity of a single pharmaceutical agent and a combination of pharmaceutical agents were drawn.

The effect of combined use of FK228 and cisplatin was
30 evaluated by isobologram analysis according to the method of Steel et al. (Int. J. Radiat. Oncol. Biol. Phys., 5: 85-91, 1979.). Namely, based on the concentration reaction curve of each single pharmaceutical agent, 80% growth inhibitory

concentration (IC_{80}) by combined use was theoretically determined and shown by curves on a graph. The concentration of a pharmaceutical agent that achieved IC_{80} in an actual combined use was plotted (see Fig. 1). When the plot was in an area (b) surrounded by the curves, an additive effect was determined to be present, when it was in an area (a) closer to the point of origin, a synergistic effect was determined to be present, and when it was in an area (c) farther from the point of origin, an antagonistic effect was determined to be present. The relative values were employed wherein IC_{80} of a single agent was 1.

The isobologram of Experimental Example 1 is shown in Fig. 2. As a result of the combined use (simultaneous addition) of FK228 and cisplatin, antitumor activity was remarkably enhanced.

Experimental Example 2: effect of combined use (continuous addition) of FK228 and cisplatin

Prostate cancer cells (6×10^3 cells/well) were cultured in a 96 well plate for 24 hr and FK228 (0.1 nM, 0.2 nM, 0.5 nM, 1 nM, 2 nM, 5 nM, 10 nM, 20 nM and 50 nM) and cisplatin (50 nM, 100 nM, 200 nM, 500 nM, 1000 nM, 2000 nM and 5000 nM) were added to achieve various concentrations. After culture for 24 hr, the cells were washed twice with 1% FBS-containing PBS(-).

After washing, FK228 and cisplatin were added by continuous addition of both pharmaceutical agents in combination (added in the order of FK228 $\Rightarrow$ cisplatin or cisplatin $\Rightarrow$ FK228 to achieve combination of each concentration). The mixture was further cultured for 24 hr and washed twice with 1% FBS-containing PBS(-). The medium was changed to a drug-free medium and the cells were further cultured for 72 hr. The effect of combined use was evaluated by a method similar to that in Experimental Example 1.

The isobologram of Experimental Example 2 is shown in Fig.

3 (addition order of FK228 $\Rightarrow$ cisplatin) and Fig. 4 (addition
order of cisplatin $\Rightarrow$ FK228). Remarkable enhancement of
antitumor activity was afforded by the combined use
(continuous addition) of FK228 and cisplatin in any order of
5 addition (addition order of FK228 $\Rightarrow$ cisplatin or
cisplatin $\Rightarrow$ FK228).

Experimental Example 3: effect of combined use (simultaneous
addition) of FK228 and 5-fluorouracil

In the same manner as in Experimental Example 1 except
10 that various concentrations of 5-fluorouracil (5 μ M, 10 μ M, 20
 μ M, 50 μ M, 100 μ M, 200 μ M and 500 μ M) were added instead of
cisplatin, the effect of the combined use was evaluated. 5-
Fluorouracil was diluted with a medium before addition.

The isobologram of Experimental Example 3 is shown in Fig.
15 5. The combined use (simultaneous addition) of FK228 and 5-
fluorouracil enhanced the antitumor activity.

Experimental Example 4: effect of combined use (continuous
addition) of FK228 and 5-fluorouracil

In the same manner as in Experimental Example 2 except
20 that various concentrations of 5-fluorouracil (5 μ M, 10 μ M, 20
 μ M, 50 μ M, 100 μ M, 200 μ M and 500 μ M for the addition order of
5-fluorouracil $\Rightarrow$ FK228; and 100 μ M, 200 μ M, 500 μ M, 1000 μ M,
2000 μ M, 5000 μ M and 10000 μ M for the addition order of
FK228 $\Rightarrow$ 5-fluorouracil) were added instead of cisplatin, the
25 effect of the combined use was evaluated. 5-Fluorouracil was
diluted with a medium before addition.

The isobologram of Experimental Example 4 is shown in Fig.
6 (addition order of FK228 $\Rightarrow$ 5-fluorouracil) and Fig. 7
(addition order of 5-fluorouracil $\Rightarrow$ FK228). The combined use
30 (continuous addition) of FK228 and 5-fluorouracil in any order
of addition (addition order of FK228 $\Rightarrow$ 5-fluorouracil or 5-
fluorouracil $\Rightarrow$ FK228) enhanced the antitumor activity.

Experimental Example 5: effect of combined use of FK228 and

paclitaxel (continuous addition in the order of
paclitaxel⇒FK228)

In the same manner as in Experimental Example 2 except
that various concentrations of paclitaxel (0.2 nM, 0.5 nM, 1
5 nM, 2 nM, 5 nM, 10 nM and 20 nM) were added in the order of
paclitaxel⇒FK228 instead of cisplatin, the effect of the
combined use was evaluated. Paclitaxel was dissolved in
ethanol and diluted with a medium before addition.

The isobologram of Experimental Example 5 is shown in Fig.
10 8. The combined use of FK228 and paclitaxel (continuous
addition in the order of paclitaxel⇒FK228) enhanced the
antitumor activity.

Formulation Example 1

FK228	20 mg
15 ethanol	20 ml

FK228 (20 mg) is dissolved in and diluted with ethanol
(20 ml) to give a preparation for injection.

Formulation Example 2

20 FK228	20 mg
cisplatin	100 mg
physiological saline	100 ml

FK228 (20 mg) and cisplatin (100 mg) are dissolved in and
25 diluted with physiological saline (100 ml) to give a
preparation for injection.

Formulation Example 3

FK228	20 mg
5-fluorouracil	500 mg
30 ethanol	100 ml

FK228 (20 mg) and 5-fluorouracil (500 mg) are dissolved
in and diluted with ethanol (100 ml) to give a preparation for

injection.

Formulation Example 4

FK228	20 mg
paclitaxel	20 mg
⁵ ethanol	40 ml

FK228 (20 mg) and paclitaxel (20 mg) are dissolved in and diluted with ethanol (40 ml) to give a preparation for injection.

¹⁰


While this invention has been shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

¹⁵

All patents, patent publications and other publications identified or referenced herein are incorporated by reference in their entirety.

CLAIMS

1. A method of treating a patient comprising administering to the patient a histone deacetylase inhibitor in combination
 5 with at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent.
- 10 2. The method as claimed in claim 1, wherein the histone deacetylase inhibitor is a compound represented by the formula (I)



- 15 its reduction product, analogs, prodrugs or a pharmaceutically acceptable salt thereof.
3. The method as claimed in claim 1 wherein the histone deacetylase inhibitor is FK228 or a pharmaceutically
 20 acceptable salt thereof.
4. The method as claimed in claim 1 wherein the histone

deacetylase inhibitor is SAHA or a pharmaceutically acceptable salt thereof.

5 5. The method as claimed in claim 2, wherein the antitumor agent that forms a cross-link with DNA and shows an antitumor effect is a platinum compound antitumor agent or an alkylating antitumor agent.

10 6. The method as claimed in claim 5, wherein the platinum compound antitumor agent is cisplatin.

7. The method as claimed in claim 2, wherein the antimetabolite antitumor agent is 5-fluorouracil.


15 8. The method as claimed in claim 2, wherein the taxane antitumor agent is at least one of paclitaxel and docetaxel.

9. The method as claimed in any of claims 1-8, which is an antitumor agent for lung cancer, malignant lymphoma, cancer of
20 digestive organ, breast cancer, ovarian cancer, musculoskeletal sarcoma, bladder cancer, leukemia, kidney cancer or prostate cancer.

10. A method for enhancing the antitumor effect for at least
25 one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, which comprises administering a histone deacetylase inhibitor as an active ingredient.

30

11. The method as claimed in claim 10, wherein the histone deacetylase inhibitor is a compound represented by the formula (I)



its reduction product, analogs, prodrugs or a pharmaceutically acceptable salt thereof.

5

12. The method as claimed in claim 10 wherein the histone deacetylase inhibitor is FK228 or a pharmaceutically acceptable salt thereof.

10 13. The method as claimed in claim 10 wherein the histone deacetylase inhibitor is SAHA or a pharmaceutically acceptable salt thereof.

14. The method as claimed in claim 11, wherein the antitumor
15 agent that forms a cross-link with DNA and shows an antitumor effect is a platinum compound antitumor agent or an alkylating antitumor agent.

15. The method as claimed in claim 14, wherein the platinum
20 compound antitumor agent is cisplatin.

16. The method as claimed in claim 11, wherein the

antimetabolite antitumor agent is 5-fluorouracil.

17. The method as claimed in claim 11, wherein the taxane antitumor agent is at least one of paclitaxel and docetaxel.


5

18. The method of any of claims 10-17, which is an antitumor effect enhancer for lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian cancer, musculoskeletal sarcoma, bladder cancer, leukemia, kidney

10 cancer or prostate cancer.

19. An antitumor agent comprising, in combination, at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and
15 shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, and a histone deacetylase inhibitor.

20. The antitumor agent as claimed in claim 19, wherein the
20 histone deacetylase inhibitor is a compound represented by the formula (I)



its reduction product, analogs, prodrugs or a pharmaceutically acceptable salt thereof.

21. The antitumor agent as claimed in claim 20, wherein the
5 antitumor agent that forms a cross-link with DNA and shows an antitumor effect is a platinum compound antitumor agent or an alkylating antitumor agent.

22. The antitumor agent as claimed in claim 21, wherein the
10 platinum compound antitumor agent is cisplatin.

23. The antitumor agent as claimed in claim 20, wherein the antimetabolite antitumor agent is 5-fluorouracil.


15 24. The antitumor agent as claimed in claim 20, wherein the taxane antitumor agent is at least one of paclitaxel and docetaxel.

25. The antitumor agent as claimed in any of claims 19-24,
20 which is an antitumor agent for lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian cancer, musculoskeletal sarcoma, bladder cancer, leukemia, kidney cancer or prostate cancer.

25 26. An antitumor effect enhancer for at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, which comprises a histone deacetylase
30 inhibitor as an active ingredient.

27. The enhancer as claimed in claim 26, wherein the histone deacetylase inhibitor is a compound represented by the formula

(I)



its reduction product, analogs, prodrugs or a pharmaceutically acceptable salt thereof.

5

28. The enhancer as claimed in claim 27, wherein the antitumor agent that forms a cross-link with DNA and shows an antitumor effect is a platinum compound antitumor agent or an alkylating antitumor agent.

10

29. The enhancer as claimed in claim 28, wherein the platinum compound antitumor agent is cisplatin.

30. The enhancer as claimed in claim 27, wherein the

15 antimetabolite antitumor agent is 5-fluorouracil.


31. The enhancer as claimed in claim 27, wherein the taxane antitumor agent is at least one of paclitaxel and docetaxel.

20 32. The enhancer of any of claims 26-31, which is an antitumor effect enhancer for lung cancer, malignant lymphoma, cancer of digestive organ, breast cancer, ovarian cancer,

musculoskeletal sarcoma, bladder cancer, leukemia, kidney cancer or prostate cancer.

33. A commercial package comprising a concomitant agent
 5 comprising at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, and a written matter associated therewith, the written matter stating that
 10 the concomitant agent can or should be used as an antitumor agent.

34. The commercial package as claimed in claim 33, wherein the histone deacetylase inhibitor is a compound represented by the
 15 formula (I)



its reduction product, analogs, prodrugs or a pharmaceutically acceptable salt thereof.

20 35. The commercial package as claimed in claim 34, wherein the antitumor agent that forms a cross-link with DNA and shows an antitumor effect is a platinum compound antitumor agent or an

alkylating antitumor agent.

36. The commercial package as claimed in claim 35, wherein the platinum compound antitumor agent is cisplatin.


5

37. The commercial package as claimed in claim 34, wherein the antimetabolite antitumor agent is 5-fluorouracil.

38. The commercial package as claimed in claim 34, wherein the
10 taxane antitumor agent is at least one of paclitaxel and docetaxel.

39. A commercial package comprising a preparation containing a histone deacetylase inhibitor and a written matter associated
15 therewith, the written matter stating that the preparation can or should be used for enhancing an antitumor effect of at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor
20 agent and a taxane antitumor agent.

40. The commercial package as claimed in claim 39, wherein the histone deacetylase inhibitor is a compound represented by the formula (I)



its reduction product, analogs, prodrugs or a pharmaceutically acceptable salt thereof.

5 41. The commercial package as claimed in claim 40, wherein the antitumor agent that forms a cross-link with DNA and shows an antitumor effect is a platinum compound antitumor agent or an alkylating antitumor agent.

10 42. The commercial package as claimed in claim 41, wherein the platinum compound antitumor agent is cisplatin.

43. The commercial package as claimed in claim 40, wherein the antimetabolite antitumor agent is 5-fluorouracil.

15

44. The commercial package as claimed in claim 40, wherein the taxane antitumor agent is at least one of paclitaxel and docetaxel.



FIG. 1**FIG. 2**



FIG. 3**FIG. 4**




FIG. 5**FIG. 6**

FIG. 7**FIG. 8**